Author

A. Vasciaveo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1

Frequent Co-Authors

A. Califano· 2 shared C. Abate-Shen· 2 shared M. A. Rubin· 2 shared M. M. Shen· 2 shared M. Zou· 2 shared A. Mitrofanova· 1 shared A. Rodriguez-Calero· 1 shared B. D. Robinson· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Califano

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 18, 2023

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

J. J. Li, A. Vasciaveo, D. Karagiannis…·M. M. Shen

This study identifies NSD2 as a key driver of lineage plasticity and castration-resistance in neuroendocrine prostate cancer, showing its inhibition can restore sensitivity to AR inhibitors.

DOI 10.1101/2023.07.18.549585

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivFeb 11, 2022

OncoLoop: A network-based precision cancer medicine framework

A. Vasciaveo, M. Zou, J. M. Arriaga…·C. Abate-Shen

OncoLoop predicts and validates drug sensitivity in tumors and their models by leveraging perturbational profiles of oncology drugs, showing success in prostate cancer models and patient cohorts.

DOI 10.1158/2159-8290.cd-22-0342

humanmouse

𝕏 PostBluesky